Emerging therapeutic targets for idiopathic pulmonary fibrosis: preclinical progress and therapeutic implications

Toyoshi Yanagihara, Ciaran Scallan, Kjetil Ask, Martin R.J. Kolb

研究成果: ジャーナルへの寄稿総説査読

6 被引用数 (Scopus)

抄録

Introduction: Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with high associated morbidity and mortality. The therapeutic landscape has significantly changed in the last 20 years with two drugs currently approved that have demonstrated the ability to slow disease progression. Despite these developments, survival in IPF is limited, so there is a major interest in therapeutic targets which could serve to open up new therapeutic avenues. Areas covered: We review the most recent information regarding drug targets and therapies currently being investigated in preclinical and early-stage clinical trials. Expert opinion: The complex pathogenesis of IPF and variability in disease course and response to therapy highlights the importance of a precision approach to therapy. Novel technologies including transcriptomics and the use of serum biomarkers, will become essential tools to guide future drug development and therapeutic decision making particularly as it pertains to combination therapy.

本文言語英語
ページ(範囲)939-948
ページ数10
ジャーナルExpert Opinion on Therapeutic Targets
25
11
DOI
出版ステータス出版済み - 2021
外部発表はい

!!!All Science Journal Classification (ASJC) codes

  • 分子医療
  • 薬理学
  • 創薬
  • 臨床生化学

フィンガープリント

「Emerging therapeutic targets for idiopathic pulmonary fibrosis: preclinical progress and therapeutic implications」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル